How Do I Manage Refractory Invasive Pulmonary Aspergillosis.
Options
BORIS DOI
Date of Publication
June 2024
Publication Type
Article
Division/Institute
Author
Vergidis, Paschalis | |
Alkhateeb, Hassan | |
Nguyen, M Hong |
Series
Clinical microbiology and infection
ISSN or ISBN (if monograph)
1469-0691
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
38286175
Uncontrolled Keywords
Description
BACKGROUND
Invasive aspergillosis is associated with significant morbidity and mortality in patients with hematologic malignancies and hematopoietic cell transplant recipients. The prognosis is worse among patients who have failed primary antifungal treatment.
OBJECTIVES
We aim to provide guidance on the diagnosis and management of refractory invasive pulmonary aspergillosis.
SOURCES
Using PubMed we performed a review of original articles, meta-analyses, and systematic reviews.
CONTENT
We discuss the diagnostic criteria for invasive pulmonary aspergillosis and the evidence on treatment of primary infection. We outline our diagnostic approach to refractory disease. We propose a treatment algorithm for refractory disease and discuss the role of experimental antifungal agents.
IMPLICATIONS
For patients with worsening disease while on antifungal therapy, a thorough diagnostic evaluation is required to confirm the diagnosis of aspergillosis and exclude another concomitant infection. Treatment should be individualized. Current options include switching to another triazole, transitioning to a lipid formulation of amphotericin B, or using combination antifungal therapy.
Invasive aspergillosis is associated with significant morbidity and mortality in patients with hematologic malignancies and hematopoietic cell transplant recipients. The prognosis is worse among patients who have failed primary antifungal treatment.
OBJECTIVES
We aim to provide guidance on the diagnosis and management of refractory invasive pulmonary aspergillosis.
SOURCES
Using PubMed we performed a review of original articles, meta-analyses, and systematic reviews.
CONTENT
We discuss the diagnostic criteria for invasive pulmonary aspergillosis and the evidence on treatment of primary infection. We outline our diagnostic approach to refractory disease. We propose a treatment algorithm for refractory disease and discuss the role of experimental antifungal agents.
IMPLICATIONS
For patients with worsening disease while on antifungal therapy, a thorough diagnostic evaluation is required to confirm the diagnosis of aspergillosis and exclude another concomitant infection. Treatment should be individualized. Current options include switching to another triazole, transitioning to a lipid formulation of amphotericin B, or using combination antifungal therapy.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
1-s2.0-S1198743X24000375-main.pdf | text | Adobe PDF | 990.31 KB | accepted |